Literature DB >> 10470976

CSF monoamine metabolite and beta endorphin levels in recently detoxified alcoholics and healthy controls: prediction of alcohol cue-induced craving?

I L Petrakis1, L Trevisan, C D'Souza, R Gil, S Krasnicki, E Webb, G Heninger, N Cooney, J H Krystal.   

Abstract

BACKGROUND: Abnormalities in central neurotransmitter systems have been described in alcohol-dependent individuals and may contribute to alcohol craving. This study compared cerebrospinal fluid (CSF) levels of monoamine metabolites and beta endorphin levels in samples from early-onset alcohol-dependent patients (n = 20), late-onset alcohol-dependent patients (n = 14), and healthy controls (n = 23). It also evaluated whether these CSF measures levels predicted the degree of craving experienced in response to an alcohol cue.
METHODS: Individuals meeting DSM-III and -IV R-criteria for alcohol dependence, 1 to 3 months postdetoxification, and healthy controls underwent a lumbar puncture. Patients also completed a cue exposure test day between 3 and 15 days later.
RESULTS: Alcohol-dependent patients had lower CSF levels of the norepinephrine metabolite MHPG compared with the healthy subjects, but this difference disappeared when differences in age between the groups were accounted for. No other group comparisons between patients and healthy subjects reached significance. CSF levels of the dopamine metabolite HVA were significantly higher in the early-onset patients compared with the late-onset patients and controls. The CSF measures did not predict the precue levels of craving, or the increase in craving after alcohol cue exposure.
CONCLUSIONS: These results are inconclusive about the role of monoaminergic dysregulation in recovering alcoholics. They also question the utility of these CSF measures to predict alcohol cue reactivity in patients who have been sober at least 1 month.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10470976

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  3 in total

1.  Central Noradrenergic Interactions with Alcohol and Regulation of Alcohol-Related Behaviors.

Authors:  Elena M Vazey; Carolina R den Hartog; David E Moorman
Journal:  Handb Exp Pharmacol       Date:  2018

2.  Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia.

Authors:  Ismene L Petrakis; Stephanie O'Malley; Bruce Rounsaville; James Poling; Colette McHugh-Strong; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

3.  Beneficial effects of low alcohol exposure, but adverse effects of high alcohol intake on glymphatic function.

Authors:  Iben Lundgaard; Wei Wang; Allison Eberhardt; Hanna Sophia Vinitsky; Benjamin Cameron Reeves; Sisi Peng; Nanhong Lou; Rashad Hussain; Maiken Nedergaard
Journal:  Sci Rep       Date:  2018-02-02       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.